Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9.

Wirsching HG, Arora S, Zhang H, Szulzewsky F, Cimino PJ, Quéva C, Houghton AM, Glorioso JC, Weller M, Holland EC.

Neuro Oncol. 2019 Aug 15. pii: noz145. doi: 10.1093/neuonc/noz145. [Epub ahead of print] No abstract available.

PMID:
31412117
2.

Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.

Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, Kumasaka D, Pierce RH, Weller M, Finer M, Quéva C, Glorioso JC, Houghton AM, Holland EC.

JCI Insight. 2019 Jul 11;4(13). pii: 128217. doi: 10.1172/jci.insight.128217. eCollection 2019 Jul 11.

3.

A novel ex vivo high-throughput assay reveals antiproliferative effects of idelalisib and ibrutinib in chronic lymphocytic leukemia.

Primo D, Scarfò L, Xochelli A, Mattsson M, Ranghetti P, Espinosa AB, Robles A, Gorrochategui J, Martínez-López J, de la Serna J, González M, Gil AC, Anguita E, Iraheta S, Munugalavadla V, Quéva C, Tannheimer S, Rosenquist R, Stamatopoulos K, Ballesteros J, Ghia P.

Oncotarget. 2018 May 25;9(40):26019-26031. doi: 10.18632/oncotarget.25419. eCollection 2018 May 25.

4.

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.

Yahiaoui A, Meadows SA, Sorensen RA, Cui ZH, Keegan KS, Brockett R, Chen G, Quéva C, Li L, Tannheimer SL.

PLoS One. 2017 Feb 8;12(2):e0171221. doi: 10.1371/journal.pone.0171221. eCollection 2017.

5.

Cardiac effect of sodium bicarbonate in sodium-channel blocker poisoning.

Lemyze M, Masse J, Queva C, Huchette D.

Intensive Care Med. 2016 Apr;42(4):588-590. doi: 10.1007/s00134-015-4122-5. Epub 2015 Nov 10. No abstract available.

PMID:
26556613
6.

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.

Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V.

Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10. Review.

7.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3.

Li Z, Wang X, Eksterowicz J, Gribble MW Jr, Alba GQ, Ayres M, Carlson TJ, Chen A, Chen X, Cho R, Connors RV, DeGraffenreid M, Deignan JT, Duquette J, Fan P, Fisher B, Fu J, Huard JN, Kaizerman J, Keegan KS, Li C, Li K, Li Y, Liang L, Liu W, Lively SE, Lo MC, Ma J, McMinn DL, Mihalic JT, Modi K, Ngo R, Pattabiraman K, Piper DE, Queva C, Ragains ML, Suchomel J, Thibault S, Walker N, Wang X, Wang Z, Wanska M, Wehn PM, Weidner MF, Zhang AJ, Zhao X, Kamb A, Wickramasinghe D, Dai K, McGee LR, Medina JC.

J Med Chem. 2014 Apr 24;57(8):3430-49. doi: 10.1021/jm500118j. Epub 2014 Apr 2.

PMID:
24641103
8.

Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.

Keegan K, Li C, Li Z, Ma J, Ragains M, Coberly S, Hollenback D, Eksterowicz J, Liang L, Weidner M, Huard J, Wang X, Alba G, Orf J, Lo MC, Zhao S, Ngo R, Chen A, Liu L, Carlson T, Quéva C, McGee LR, Medina J, Kamb A, Wickramasinghe D, Dai K.

Mol Cancer Ther. 2014 Apr;13(4):880-9. doi: 10.1158/1535-7163.MCT-13-0858. Epub 2014 Feb 13.

9.

Macrophage migration inhibitory factor produced by the tumour stroma but not by tumour cells regulates angiogenesis in the B16-F10 melanoma model.

Girard E, Strathdee C, Trueblood E, Quéva C.

Br J Cancer. 2012 Oct 23;107(9):1498-505. doi: 10.1038/bjc.2012.392. Epub 2012 Sep 6.

10.

Peptibodies: A flexible alternative format to antibodies.

Shimamoto G, Gegg C, Boone T, Quéva C.

MAbs. 2012 Sep-Oct;4(5):586-91. doi: 10.4161/mabs.21024. Epub 2012 Jul 23. Review.

11.

Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.

Bornstein GG, Quéva C, Tabrizi M, van Abbema A, Chavez C, Wang P, Foord O, Ahluwalia K, Laing N, Raja S, Wen S, Green LL, Yang X, Webster C, Stewart R, Blakey D.

Invest New Drugs. 2010 Oct;28(5):561-74. doi: 10.1007/s10637-009-9291-z. Epub 2009 Jul 21.

PMID:
19626278
12.

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.

Zabludoff SD, Deng C, Grondine MR, Sheehy AM, Ashwell S, Caleb BL, Green S, Haye HR, Horn CL, Janetka JW, Liu D, Mouchet E, Ready S, Rosenthal JL, Queva C, Schwartz GK, Taylor KJ, Tse AN, Walker GE, White AM.

Mol Cancer Ther. 2008 Sep;7(9):2955-66. doi: 10.1158/1535-7163.MCT-08-0492.

13.

Effects of GABA agonists on body temperature regulation in GABA(B(1))-/- mice.

Quéva C, Bremner-Danielsen M, Edlund A, Ekstrand AJ, Elg S, Erickson S, Johansson T, Lehmann A, Mattsson JP.

Br J Pharmacol. 2003 Sep;140(2):315-22. Epub 2003 Aug 11.

14.

Amphicoup-TF, a nuclear orphan receptor of the lancelet Branchiostoma floridae, is implicated in retinoic acid signalling pathways.

Langlois MC, Vanacker JM, Holland ND, Escriva H, Queva C, Laudet V, Holland LZ.

Dev Genes Evol. 2000 Oct;210(10):471-82.

PMID:
11180796
15.
16.

Dwarfism and dysregulated proliferation in mice overexpressing the MYC antagonist MAD1.

Quéva C, McArthur GA, Ramos LS, Eisenman RN.

Cell Growth Differ. 1999 Dec;10(12):785-96.

17.

Mlx, a novel Max-like BHLHZip protein that interacts with the Max network of transcription factors.

Billin AN, Eilers AL, Queva C, Ayer DE.

J Biol Chem. 1999 Dec 17;274(51):36344-50.

18.

The Mad protein family links transcriptional repression to cell differentiation.

McArthur GA, Laherty CD, Quéva C, Hurlin PJ, Loo L, James L, Grandori C, Gallant P, Shiio Y, Hokanson WC, Bush AC, Cheng PF, Lawrence QA, Pulverer B, Koskinen PJ, Foley KP, Ayer DE, Eisenman RN.

Cold Spring Harb Symp Quant Biol. 1998;63:423-33. Review. No abstract available.

PMID:
10384307
19.

Sequential expression of the MAD family of transcriptional repressors during differentiation and development.

Quéva C, Hurlin PJ, Foley KP, Eisenman RN.

Oncogene. 1998 Feb 26;16(8):967-77.

20.

Targeted disruption of the MYC antagonist MAD1 inhibits cell cycle exit during granulocyte differentiation.

Foley KP, McArthur GA, Quéva C, Hurlin PJ, Soriano P, Eisenman RN.

EMBO J. 1998 Feb 2;17(3):774-85.

21.

The ETS1 transcription factor is expressed during epithelial-mesenchymal transitions in the chick embryo and is activated in scatter factor-stimulated MDCK epithelial cells.

Fafeur V, Tulasne D, Quéva C, Vercamer C, Dimster V, Mattot V, Stéhelin D, Desbiens X, Vandenbunder B.

Cell Growth Differ. 1997 Jun;8(6):655-65.

22.

Mnt: a novel Max-interacting protein and Myc antagonist.

Hurlin PJ, Qúeva C, Eisenman RN.

Curr Top Microbiol Immunol. 1997;224:115-21.

PMID:
9308234
24.

Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.

Hurlin PJ, Quéva C, Koskinen PJ, Steingrímsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN.

EMBO J. 1996 Apr 15;15(8):2030. No abstract available.

25.

Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation.

Hurlin PJ, Quéva C, Koskinen PJ, Steingrímsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN.

EMBO J. 1995 Nov 15;14(22):5646-59. Erratum in: EMBO J. 1996 Apr 15;15(8):2030.

26.

Expression of the transcription factor c-Ets1 correlates with the occurrence of invasive processes during normal and pathological development.

Vandenbunder B, Queva C, Desbiens X, Wernert N, Stehelin D.

Invasion Metastasis. 1994-1995;14(1-6):198-209. Review.

PMID:
7657513
27.

Does the transcription factor c-ets1 take part in the regulation of angiogenesis and tumor invasion?

Vandenbunder B, Wernert N, Queva C, Desbiens X, Stehelin D.

Folia Biol (Praha). 1994;40(5):301-13. Review.

PMID:
7534726
28.
29.

Expression patterns of c-myb and of v-myb induced myeloid-1 (mim-1) gene during the development of the chick embryo.

Quéva C, Ness SA, Grässer FA, Graf T, Vandenbunder B, Stéhelin D.

Development. 1992 Jan;114(1):125-33.

30.

Supplemental Content

Support Center